GGrantIndex
← Leaderboards

Jeffrey A Toretsky

University Of Maryland Baltimore

$12,946,273
Attributed
$12,946,273
Total exposure
12
Grants
11
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $5.2M · FY200525
$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$13,266,273 · 13

By mechanism

R01$7,510,821 · 4
RC4$4,374,674 · 1
S10$640,000 · 5
R41$596,620 · 1
P30$138,158 · 1
R13$6,000 · 1

Top collaborators

No co-investigators on record.

Most similar at University Of Maryland Baltimore

Same institution · by research overlap

Others in their field

Top investigators on “Ews-Fli1 Fusion Protein

Research focus

Ews-Fli1 Fusion ProteinLeadTumorChimeric ProteinsCellsMalignant NeoplasmsEwings SarcomaOncogenicClinical TrialsSarcomaSmall MoleculeRna Helicase AChromosomal TranslocationTranscription FactorProtein Protein InteractionInhibitor/AntagonistProteinsGrowthPathway InteractionsCancer PatientCessation Of LifeGenesComplexTumorigenesis

Grant awards (35)

Dissection of EWS-FLI1 oncogenic mechanisms and small molecule targeting$159,282
R01 · FY2025 · CA · contact PI
Dissection of EWS-FLI1 oncogenic mechanisms and small molecule targeting$196,058
R01 · FY2024 · CA · contact PI
Dissection of EWS-FLI1 oncogenic mechanisms and small molecule targeting$363,883
R01 · FY2023 · CA · contact PI
Dissection of EWS-FLI1 oncogenic mechanisms and small molecule targeting$363,883
R01 · FY2022 · CA · contact PI
Dissection of EWS-FLI1 oncogenic mechanisms and small molecule targeting$371,310
R01 · FY2021 · CA · contact PI
Dissection of EWS-FLI1 oncogenic mechanisms and small molecule targeting$416,086
R01 · FY2020 · CA · contact PI
Research Program - Molecular Oncology$69,079
P30 · FY2020 · CA · contact PI
Research Program - Molecular Oncology$69,079
P30 · FY2019 · CA · contact PI
Phase separation and RNA processingas drivers of cancer and neurodegenerative disease$6,000
R13 · FY2017 · CA · contact PI
Novel Compounds to Inactivate Oncogenic Fusion Proteins$290,421
R01 · FY2013 · CA · contact PI
Isolation and small molecule targeting of Ewing's Sarcoma stem cells$457,435
R01 · FY2012 · CA · contact PI
Novel Compounds to Inactivate Oncogenic Fusion Proteins$308,958
R01 · FY2012 · CA · contact PI
Isolation and small molecule targeting of Ewing's Sarcoma stem cells$461,919
R01 · FY2011 · CA · contact PI
Novel Compounds to Inactivate Oncogenic Fusion Proteins$308,958
R01 · FY2011 · CA · contact PI
YK-4-279 specifically targets ETS family fusion-protein cancers in clinical trial$4,374,674
RC4 · FY2010 · CA · contact PI
Isolation and small molecule targeting of Ewing's Sarcoma stem cells$490,492
R01 · FY2010 · CA · contact PI
Novel Compounds to Inactivate Oncogenic Fusion Proteins$318,513
R01 · FY2010 · CA · contact PI
Isolation and small molecule targeting of Ewing's Sarcoma stem cells$495,302
R01 · FY2009 · CA · contact PI
Novel Compounds to Inactivate Oncogenic Fusion Proteins$318,513
R01 · FY2009 · CA · contact PI
Isolation and small molecule targeting of Ewing's Sarcoma stem cells$508,677
R01 · FY2008 · CA · contact PI
Signaling Pathways that Determine Ewings Sarcoma Outcome$222,607
R01 · FY2008 · CA · contact PI
Signaling Pathways that Determine Ewings Sarcoma Outcome$223,248
R01 · FY2007 · CA · contact PI
Biacore T100$320,000
S10 · FY2006 · RR · contact PI
Signaling Pathways that Determine Ewings Sarcoma Outcome$230,558
R01 · FY2006 · CA · contact PI
BIACORE T100: CANCER$150,400
S10 · FY2006 · RR · contact PI
BIACORE T100: PROTEOMICS$99,200
S10 · FY2006 · RR · contact PI
BIACORE T100: BREAST CANCER$64,000
S10 · FY2006 · RR · contact PI
BIACORE T100: PROSTATE CANCER$6,400
S10 · FY2006 · RR · contact PI
Akt Inhibitors to Treat Ewing's Sarcoma$298,310
R41 · FY2005 · CA
Signaling Pathways that Determine Ewings Sarcoma Outcome$236,745
R01 · FY2005 · CA
Akt Inhibitors to Treat Ewing's Sarcoma$298,310
R41 · FY2004 · CA
Signaling Pathways that Determine Ewings Sarcoma Outcome$250,474
R01 · FY2004 · CA
ROLE OF IGF SIGNALING UPON EWINGS SARCOMA PATIENT$196,716
R01 · FY2003 · CA
ROLE OF IGF SIGNALING UPON EWINGS SARCOMA PATIENT$163,930
R01 · FY2002 · CA
ROLE OF IGF SIGNALING UPON EWINGS SARCOMA PATIENT$156,853
R01 · FY2001 · CA